Last reviewed · How we verify
Olaratumab and Trabectedin
At a glance
| Generic name | Olaratumab and Trabectedin |
|---|---|
| Also known as | Lartruvo and Yondelis |
| Sponsor | Grupo Espanol de Investigacion en Sarcomas |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients (PHASE1)
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (PHASE1)
- Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olaratumab and Trabectedin CI brief — competitive landscape report
- Olaratumab and Trabectedin updates RSS · CI watch RSS
- Grupo Espanol de Investigacion en Sarcomas portfolio CI